

Althea Achieves 650 Patient Milestone

Investment Highlights:


- 651 Patients have now been prescribed Althea medicinal cannabis products
- 145 Healthcare Professionals have prescribed Althea medicinal cannabis
- 140 patients were added between April 4 and April 26 (inclusive), representing 10 new patients per business day
- Australia the fastest growing global market in the world (by percentage month-on-month growth)¹
- Althea currently recruiting additional staff to capitalise on increased demand

Monday 29 April 2019: **Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company')** is pleased to provide the following update regarding the uptake of its medicinal cannabis products in Australia.

The Company is excited to announce that it has achieved the 650-patient milestone. 140 patients were added between April 4 and April 26 (inclusive) representing 10 new patients per business day. In addition to Althea passing the 650-patient mark, there are now 145 Healthcare Professionals (**HCPs**) who have prescribed Althea's products.

Althea COO Patty Holmes said: "The rapid uptake has been driven by our Medical Science Liaison (MSL) team on the ground and *Althea Concierge*, the Company's proprietary platform that allows patients, doctors and pharmacies to manage their medicinal cannabis needs in Australia. A key benefit of *Althea Concierge* is that it is able to greatly reduce application times for HCP's looking to prescribe medicinal cannabis. Due to the increase in demand for our services, we are currently recruiting more MSL's to further enhance our market leading position."

Chart 1: Patient Growth



¹ Source: Cannvalate Australia, *What, Where, Who and How of the Australian MC Industry* presentation, March 2019

Althea CEO & Managing Director Josh Fegan added: “Following the strong growth in Q3 FY19 that saw us pass the 500-patient mark, we are very happy to see further acceleration in the growth rate of patients in the first weeks of Q4 FY19. Our team continues to focus on educating Healthcare Professionals about the benefits of Althea’s pharma-grade medicinal cannabis products and providing support to the patients who require them. The ease of use of *Althea Concierge* has also been a key factor in our success and is complementary to our RACGP and ACRRM accredited medicinal education portal, *MEDIC*. I look forward to providing the next update on Althea’s increasing uptake soon.”

Ends

For further information, please contact:

Althea

Josh Fegan

CEO & Managing Director
M: 1300 70 20 20
E: contact@althea.com.au

Media Enquiries

Julia Maguire

The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities

M: 03 8633 9834
E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is a patient-focussed medicinal cannabis company. Althea has become a leading supplier of medicinal cannabis products in Australia since it was founded in Melbourne in 2017 and was granted necessary licences and permits to import, cultivate, manufacture and supply medicinal cannabis for eligible patients in Australia in 2018. Through strategic supply and distribution partnerships, Althea has become a significant supplier of five Althea branded medicinal cannabis products in Australia.

Althea’s focus on patient care underpins its business strategy and its innovative web-based platform and mobile application, known as Althea Concierge, is designed to educate and support patient access to medicinal cannabis in Australia and the United Kingdom. Althea has also engaged a team of medical science liaisons to assist medical practitioners to become prescribers, and pharmacists to become suppliers, of Althea products.

To learn more, please visit: www.althea.com.au